Goldstein Advisors LLC Has $529,000 Stock Holdings in Exact Sciences Corporation $EXAS

Goldstein Advisors LLC lessened its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 18.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 9,956 shares of the medical research company’s stock after selling 2,298 shares during the quarter. Goldstein Advisors LLC’s holdings in Exact Sciences were worth $529,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Exact Sciences by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 17,637,674 shares of the medical research company’s stock worth $763,535,000 after buying an additional 617,384 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Exact Sciences by 11.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,403,872 shares of the medical research company’s stock worth $277,225,000 after acquiring an additional 643,631 shares during the period. Mackenzie Financial Corp increased its position in Exact Sciences by 12.4% during the first quarter. Mackenzie Financial Corp now owns 3,281,639 shares of the medical research company’s stock worth $142,062,000 after acquiring an additional 362,314 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Exact Sciences by 120.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company’s stock worth $135,453,000 after acquiring an additional 1,707,287 shares during the period. Finally, Armistice Capital LLC increased its position in Exact Sciences by 9.6% during the first quarter. Armistice Capital LLC now owns 1,772,369 shares of the medical research company’s stock worth $76,726,000 after acquiring an additional 155,369 shares during the period. Institutional investors and hedge funds own 88.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on EXAS. Piper Sandler raised their price target on shares of Exact Sciences from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 8th. UBS Group lowered their price target on shares of Exact Sciences from $61.00 to $53.00 and set a “neutral” rating on the stock in a research report on Thursday, August 7th. Cowen reaffirmed a “buy” rating on shares of Exact Sciences in a research report on Thursday, August 7th. Wells Fargo & Company set a $68.00 price target on shares of Exact Sciences in a research report on Wednesday, October 1st. Finally, BTIG Research lowered their price target on shares of Exact Sciences from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $69.19.

Exact Sciences Price Performance

EXAS stock opened at $61.23 on Friday. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. Exact Sciences Corporation has a 12 month low of $38.81 and a 12 month high of $72.83. The firm has a market cap of $11.59 billion, a P/E ratio of -11.28, a P/E/G ratio of 5.65 and a beta of 1.24. The company’s 50-day moving average price is $52.24 and its two-hundred day moving average price is $51.12.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, August 6th. The medical research company reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.24. The firm had revenue of $811.09 million for the quarter, compared to analyst estimates of $774.43 million. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) EPS. On average, analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Insider Activity

In related news, Director James Edward Doyle sold 2,000 shares of Exact Sciences stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the sale, the director directly owned 57,962 shares of the company’s stock, valued at approximately $3,477,720. The trade was a 3.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.20% of the company’s stock.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.